Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Confirmatory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies.(Phase 3 study)

X
Trial Profile

Confirmatory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies.(Phase 3 study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zonisamide (Primary)
  • Indications Lewy body disease; Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Sumitomo Dainippon Pharma
  • Most Recent Events

    • 01 Mar 2022 Results(n=335)evaluating the long-term efficacy and safety of zonisamide in dementia with Lewy bodies, published in the American Journal of Geriatric Psychiatry
    • 26 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 06 Apr 2017 According to a Sumitomo Dainippon Pharma media release, an extension study is ongoing.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top